EUVIMEDEUVIMED entdecken
Multizentrische Studie

The Association between High-Dose Allopurinol and Erythropoietin Hyporesponsiveness in Advanced Chronic Kidney Disease: JOINT-KD Study

Megumi Oikawa, Hiroki Nishiwaki, Takeshi Hasegawa, Sho Sasaki, Masahiko Yazawa, Hitoshi Miyazato, Yosuke Saka, Hideaki Shimizu, Yoshiro Fujita, Minoru Murakami, Daisuke Uchida, Hiroo Kawarazaki und 4 weitere

Nephron · 2024

DOI: 10.1159/000535874 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Nephron, 2024. Verfasst von Megumi Oikawa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan. Hauptthemen laut MEDLINE: Allopurinol, Renal Insufficiency, Chronic, Erythropoietin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of the study was to explore the association between urate-lowering agents and reduced response to erythropoietin-stimulating agents in patients suffering from chronic kidney disease G5.

Methods

We conducted a cross-sectional, multicenter study in Japan between April and June 2013, enrolling patients aged 20 years or older with an estimated glomerular filtration rate of ≤15 mL/min/1.73 m2. Exclusion criteria encompassed patients with a history of hemodialysis, peritoneal dialysis, or organ transplantation. The patients were categorized into four groups based on the use of urate-lowering drugs: high-dose allopurinol (>50 mg/day), low-dose allopurinol (≤50 mg/day), febuxostat, and no-treatment groups. We used a multivariable logistic regression model, adjusted for covariates, to determine the odds ratio (OR) for erythropoietin hyporesponsiveness, defined by an erythropoietin resistance index (ERI) of ≥10, associated with urate-lowering drugs.

Results

A total of 542 patients were included in the analysis, with 105, 36, 165, and 236 patients in the high-dose allopurinol, low-dose allopurinol, febuxostat, and no-treatment groups, respectively. The median and quartiles of ERIs were 6.3 (0, 12.2), 3.8 (0, 11.2), 3.4 (0, 9.8), and 4.8 (0, 11.2) in the high-dose allopurinol, low-dose allopurinol, febuxostat, and no-treatment groups, respectively. The multivariate regression model showed a statistically significant association between the high-dose allopurinol group and erythropoietin hyporesponsiveness, compared to the no-treatment group (OR = 1.98, 95% confidence interval: 1.10–3.57).

Conclusions

Our study suggests that the use of high-dose allopurinol exceeding the optimal dose may lead to hyporesponsiveness to erythropoiesis-stimulating agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AllopurinolRenal Insufficiency, ChronicErythropoietinHumansMaleFemaleMiddle AgedAgedCross-Sectional StudiesGout SuppressantsAdultDose-Response Relationship, DrugUric AcidHematinicsJapanFebuxostat

Stichwörter der Autor:innen

AllopurinolChronic kidney diseaseErythropoiesis-stimulating agentsHyporesponsivenessUric acid-lowering drugs

Substanzen

AllopurinolErythropoietinGout SuppressantsUric AcidHematinicsFebuxostat

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Showa University Research Administration Center (SURAC), Showa University, Tokyo, Japan.
  • Department of Nephrology, Aso Iizuka Hospital, Iizuka, Japan.
  • Clinical Research Support Office, Aso Iizuka Hospital, Iizuka, Japan.
  • Department of Healthcare Epidemiology, Kyoto University Graduate School of Public Health, Kyoto, Japan.
  • Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.

Zitieren

APA

Oikawa, M., Nishiwaki, H., Hasegawa, T., Sasaki, S., Yazawa, M., Miyazato, H., Saka, Y., Shimizu, H., Fujita, Y., Murakami, M., Uchida, D., Kawarazaki, H., Omiya, S., Sasai, F., Koiwa, F., & JOINT-KD Investigators (2024). The Association between High-Dose Allopurinol and Erythropoietin Hyporesponsiveness in Advanced Chronic Kidney Disease: JOINT-KD Study. Nephron. https://doi.org/10.1159/000535874

Vancouver

Oikawa M, Nishiwaki H, Hasegawa T, Sasaki S, Yazawa M, Miyazato H, et al. The Association between High-Dose Allopurinol and Erythropoietin Hyporesponsiveness in Advanced Chronic Kidney Disease: JOINT-KD Study. Nephron. 2024. doi:10.1159/000535874

BibTeX
@article{Oikawa2024,
  author = {Oikawa, Megumi and Nishiwaki, Hiroki and Hasegawa, Takeshi and Sasaki, Sho and Yazawa, Masahiko and Miyazato, Hitoshi and Saka, Yosuke and Shimizu, Hideaki and Fujita, Yoshiro and Murakami, Minoru and Uchida, Daisuke and Kawarazaki, Hiroo and Omiya, Shinya and Sasai, Fumihiko and Koiwa, Fumihiko and JOINT-KD Investigators, JOINT-KD Investigators},
  title = {The Association between High-Dose Allopurinol and Erythropoietin Hyporesponsiveness in Advanced Chronic Kidney Disease: JOINT-KD Study},
  journal = {Nephron},
  year = {2024},
  doi = {10.1159/000535874}
}
Kostenlos starten →